Lawmakers say TikTok 'beholden' to Beijing as TikTok CEO Shou Chew testifies

Detailed updates on the high-stakes House Energy and Commerce Committee hearing.

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD

Visitors trend2W10W9M

40.38

+0.37

(+0.91%)

As of 11:21AM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	40.01
Open	40.17
Bid	40.41 x 1800
Ask	40.42 x 2900
Day's Range	40.13 - 40.50
52 Week Range	39.23 - 56.32
Volume	3,783,186
Avg. Volume	22,962,442

Market Cap	227.893B
Beta (5Y Monthly)	0.59
PE Ratio (TTM)	7.41
EPS (TTM)	5.45
Earnings Date	May 02, 2023
Forward Dividend & Yield	1.64 (4.02%)
Ex-Dividend Date	Jan 26, 2023
1y Target Est	50.97

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

1% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PFE

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Pfizer, Inc.
Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Rating
Fair Value
Economic Moat
10 days agoMorningstar

All

AP Finance
Senators press Moderna CEO on COVID-19 vaccine price hike
Moderna’s CEO on Wednesday defended a plan to more than quadruple the company’s COVID-19 vaccine price, but he also said the drugmaker will work to ensure patients continue paying nothing at drugstores or clinics. Stephane Bancel told the Senate Committee on Health, Education, Labor and Pensions that the drugmaker will charge a list price of around $130 per dose for the vaccine in the U.S. More than 270 million doses of Moderna’s original COVID-19 vaccine and booster shots have been administered in the U.S., according to the U.S. Centers for Disease Control and Prevention.
- Moderna CEO Blasted for Planned Covid Vaccine Price Hike
  The Fiscal Times
- Moderna CEO defends $130 US COVID vaccine price in Senate hearing
  Reuters
Investor's Business Daily
Is Pfizer Stock A Buy Or A Sell On Its Looming $43 Billion Seagen Takeover?
Is Pfizer stock a buy or a sell after the company announced its $43 billion plan to buy Seagen? Is PFE stock a buy or a sell?
Reuters
UPDATE 1-US declines to force lower price on cancer drug Xtandi
The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, a federal agency said on Tuesday. The Union for Affordable Cancer Treatment, a patient group, had first filed a petition calling on the National Institutes of Health (NIH) to use its authority to lower the drug's price in March 2016. The NIH said in a letter made public on Tuesday that its analyses in response to the petition found that the prostate cancer treatment was widely available.